In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
ORGANIZATION
JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
The Japan Pharmaceutical Manufacturers Association (JPMA) unveiled its fresh proposal on August 30, calling for introducing a new value-based pricing system for innovative medicines and excluding patent-protected drugs from the current market price-based NHI price revisions. The outline of the…
To read the full story
Related Article
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
ORGANIZATION
- Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
February 14, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
- Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
February 10, 2025
- Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
February 5, 2025
- Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
January 29, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…